U. Herrlinger

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
U Herrlinger, U. Herrlinger, Ulrich Herrlinger
Publication record
345 papers · 12,882 citations · H-index 59

PAPERS

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
20260 citationsauthor #27
Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma
202434 citationsauthor #10
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
20235 citationsauthor #27
Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease
202311 citationsauthor #11
Gliosarcoma with extensive extracranial metastatic spread and familial coincidence: A case report.
20231 citationsauthor #11
Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations
20235 citationsauthor #17
Incurring detriments of unplanned readmission to the intensive care unit following surgery for brain metastasis
20236 citationsauthor #10
Distress in Neuro-Oncology Patients and Its Implications for Communication
20231 citationsauthor #11
P11.65.B TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSEDMGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS
20230 citationsauthor #17
Five-Fraction Stereotactic Radiotherapy for Brain Metastases—A Retrospective Analysis
20237 citationsauthor #16
Unplanned intensive care unit readmission after surgical treatment in patients with newly diagnosed glioblastoma — forfeiture of surgically achieved advantages?
202310 citationsauthor #11
P11.21.A LONG-TERM SURVIVAL WITH IDH WILDTYPE GLIOBLASTOMA: FIRST RESULTS FROM THE ETERNITY BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM (EORTC 1419)
20230 citationsauthor #25
Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.
20235 citationsauthor #19
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
20231 citationsauthor #9
Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis
202315 citationsauthor #23
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
202361 citationsauthor #25
PO-1088 Impact of nationality on the quality of early side effects following radiotherapy in Germany
20230 citationsauthor #12
Survival in patients with surgically treated brain metastases: does infratentorial location matter?
20238 citationsauthor #7
Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
20231 citationsauthor #16
Detection of vincristine-induced neuropathy in patients with oligodendroglioma.
20222 citationsauthor #2
NIMG-32. POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL
20220 citationsauthor #23
MAC-spinal meningioma score: A proposal for a quick-to-use scoring sheet of the MIB-1 index in sporadic spinal meningiomas
20222 citationsauthor #7
185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
20220 citationsauthor #11
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
202214 citationsauthor #18
Preoperative Risk Stratification of Increased MIB-1 Labeling Index in Pituitary Adenoma: A Newly Proposed Prognostic Scoring System
20220 citationsauthor #4
Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
20225 citationsauthor #4
Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Location—From Convexity to Skull Base and Spine
202215 citationsauthor #5
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma
20227 citationsauthor #7
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression
202217 citationsauthor #18
170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study
20221 citationsauthor #9
Inflammatory Tumor Microenvironment in Cranial Meningiomas: Clinical Implications and Intraindividual Reproducibility
20223 citationsauthor #5
CTNI-07. LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT
20220 citationsauthor #43
Benchmarking Safety Indicators of Surgical Treatment of Brain Metastases Combined with Intraoperative Radiotherapy: Results of Prospective Observational Study with Comparative Matched-Pair Analysis
202218 citationsauthor #17
CTNI-67. DUAL INHIBITION OF POST-RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA – INTERIM DATA FROM THE FIRST EXPANSION ARM OF THE GERMAN PHASE 1/2 GLORIA TRIAL
20220 citationsauthor #22
Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience
202217 citationsauthor #29
PO-1160 Chasing a rarity: a retrospective single centre evaluation of prognostic factors in gliosarcoma
20220 citationsauthor #4
In Vivo Quantitative Imaging of Glioma Heterogeneity Employing Positron Emission Tomography
20224 citationsauthor #5
Methylation class oligosarcoma may encompass IDH-wildtype gliomas
20223 citationsauthor #2
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
20228 citationsauthor #9
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
202214 citationsauthor #11
Cost Effectiveness of 18F-FET PET for Early Treatment Response Assessment in Glioma Patients After Adjuvant Temozolomide Chemotherapy
202216 citationsauthor #9
P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosedMGMT promoter methylatedIDH wildtype glioblastoma
20220 citationsauthor #17
642 EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 EOGBM1–18/ROSALIE study
20225 citationsauthor #9
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
202225 citationsauthor #31
Disconnecting multicellular networks in brain tumours
202292 citationsauthor #6
Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma
20225 citationsauthor #5
641 Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study
20223 citationsauthor #12
Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC)
20228 citationsauthor #11
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
20225 citationsauthor #18
Increased MIB-1 Labeling Index Is Associated with Abducens Nerve Morbidity in Primary Sporadic Petroclival Meningioma Surgery: Beyond Location and Approach
20221 citationsauthor #5
Postoperative prolonged mechanical ventilation correlates to poor survival in patients with surgically treated spinal metastasis
20224 citationsauthor #10
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany
20214 citationsauthor #11
Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas
20213 citationsauthor #10
Chemotherapy for adult patients with spinal cord gliomas.
20214 citationsauthor #8
BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA
20210 citationsauthor #29
Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma
20216 citationsauthor #10
Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom
202113 citationsauthor #8
The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)
202146 citationsauthor #4
Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases
202117 citationsauthor #17
Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection
202128 citationsauthor #9
P14.11 Severe treatment-induced myelosuppression is more frequent in female malignant glioma patients and associated with reduced overall survival
20210 citationsauthor #6
BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS
20210 citationsauthor #17
Erratum to: Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
20211 citationsauthor #14
Outcome of Elderly Patients With Surgically Treated Brain Metastases
202121 citationsauthor #16
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status
202122 citationsauthor #17
Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma
202114 citationsauthor #12
Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography
202112 citationsauthor #19
The value of bone marrow biopsy for staging of patients with primary CNS lymphoma
202111 citationsauthor #9
Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis
202126 citationsauthor #16
Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma
20217 citationsauthor #11
Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma
202114 citationsauthor #7
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
2021212 citationsauthor #28
FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in Intracranial Meningiomas
202112 citationsauthor #6
The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival
20211 citationsauthor #15
Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications
202123 citationsauthor #9
Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey
202123 citationsauthor #13
Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma
20214 citationsauthor #13
The Impact of Prolonged Mechanical Ventilation on Overall Survival in Patients With Surgically Treated Brain Metastases
202114 citationsauthor #18
Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma
202117 citationsauthor #6
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
202143 citationsauthor #29
Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis
202127 citationsauthor #18
Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma
20216 citationsauthor #5
Prognostic factors in leptomeningeal metastases.
20211 citationsauthor #14
Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
202127 citationsauthor #17
East meets West for the treatment of glioma: A discussion of real-world cases
20200 citationsauthor #6
A Matched-pair Analysis on the Effect of Migration Background on Response Rates and Survival of Cancer Patients Treated at a Comprehensive Cancer Center in Germany
20200 citationsauthor #11
Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
202023 citationsauthor #7
A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
202033 citationsauthor #9
News on the horizon in glioblastoma therapy
20202 citationsauthor #1
NIMG-14. MACHINE LEARNING-BASED EVALUATION OF STATIC AND DYNAMIC FET-PET FOR THE DETECTION OF PSEUDOPROGRESSION IN PATIENTS WITH IDH-WILDTYPE GLIOBLASTOMA
20200 citationsauthor #9
Postoperative Prolonged Mechanical Ventilation in Patients With Newly Diagnosed Glioblastoma—An Unrecognized Prognostic Factor
202012 citationsauthor #13
BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE
20200 citationsauthor #10
Impact of initial midline shift in glioblastoma on survival
202019 citationsauthor #5
Treatment of metastasized melanoma with combined checkpoint inhibition in a patient with highly active multiple sclerosis
20202 citationsauthor #6
Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol
202024 citationsauthor #12
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma
202016 citationsauthor #13
Early Treatment Response Assessment Using 18F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
202034 citationsauthor #10
372MO Melanoma leptomeningeal metastases: A European multicenter cohort
20200 citationsauthor #10
Comorbidity Burden and Presence of Multiple Intracranial Lesions Are Associated with Adverse Events after Surgical Treatment of Patients with Brain Metastases
202027 citationsauthor #16
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial
202012 citationsauthor #23

TIMELINE

1996 27 citations

1997 120 citations

1998 199 citations

1999 98 citations

2000 51 citations

2001 306 citations

2002 272 citations

2003 91 citations

2004 744 citations

2005 969 citations

2006 555 citations

2007 577 citations

2008 486 citations

2009 208 citations

2010 1,096 citations

2011 103 citations

2012 87 citations

2013 143 citations

2014 1,128 citations

2015 1,339 citations

2016 791 citations

2017 649 citations

2018 259 citations

2019 923 citations

2020 534 citations

2021 659 citations

2022 294 citations

2023 137 citations

2024 34 citations

2026 0 citations

Unknown 1 citations

U. Herrlinger

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT